Transcatheter Aortic Valve Replacement Outcome in Peripheral Vascular Disease Patients

Darmoch, Fahed

Transcatheter Aortic Valve Replacement Outcome in Peripheral Vascular Disease Patients

Wednesday, May 22, 2019

Belmont Ballroom 2-3 (The Cosmopolitan of Las Vegas)

Fahed Darmoch, M.D. , Beth Israel Deaconess/Harvard Medical School, Boston, MA

Yasser Al-khadra, M.D. , Cleveland Clinic Foundation, Cleveland, OH

Homam Moussa Pacha , Medstar Institute, Washington Hospital Center, Washington, DC

Mohamad Soud, M.D. , Washingtom Hospital Center, Washigton, DC

Amir Kaki, M.D., FSCAI, FSCAI , Lenox Hill Hospital, Birmingham, MI

Chun Shing Kwok , Keele Cardiovascular Research Group, Keele University, t, United Kingdom, Stoke-on-Trent, United Kingdom

Mamas A. Mamas, M.D. , Keele University, Stoke-on-Trent, United Kingdom

Wael AlJaroud , Clemenceau Medical Center, Beirut, Lebanon

Duane S. Pinto, M.D., FSCAI , Beth Israel Deaconess Medical Center, Boston, MA

M. Chadi Alraies, M.D. , Detroit Medical Center Heart Hospital, Detroit, MI

Background
Peripheral vascular disease (PVD) is a common disease in patient referred for transcatheter aortic valve replacement (TAVR). We sought to investigate the impact of PVD on patients who underwent TAVR

Methods
Using data from the National Inpatient Sample (NIS) database 2011 and 2014, we identified patients who underwent TAVR. Propensity match scoring analysis of in-hospital mortality were conducted to investigate the mortality in PVD patients who underwent TAVR procedure.

Results
A total of 1,388 patients underwent TAVR. Out of which 694 patients had PVD and 694 had no PVD. The studied population had a mean age of 81 years, 55.8% were females and 4.3% were African Americans. Propensity match scoring analysis revealed worse TAVR outcome in PVD patients with higher in-hospital mortality (5.5% vs. 3.6%, P < 0.121), vascular complication (11.8% Vs 5.9% P < 0.001) and blood transfusion (13.5% Vs 12.0% P < 0.001) compared with non-PVD patients

Conclusions
PVD is an independent risk factor for in hospital mortality, vascular complications and post procedural bleeding in patients who underwent TAVR procedure.